Michael A. Matter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael A. Matter has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Christian M. Matter
Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich, University of Zurich, Zurich, Switzerland
4 shared publications Christian Templin
Department of Cardiology Zurich and Center for Translational and Experimental Cardiology, University Hospital Zurich University of Zurich Zurich Switzerland
2 shared publications- Fabian Laumer
ETH Zurich, Institute for Machine Learning, Zurich, Switzerland
2 shared publications Frank Ruschitzka
University Hospital Zurich and University of Zurich, Center for Translational and Experimental Cardiology, Zürich, Switzerland
2 shared publications- Frank Ruschitzka
Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
2 shared publications - François Mach
Cardiology Department, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland
2 shared publications
Latest Publications
- Open Access
- 23 September 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (12) , 1809-1811
oxLDL-induced aortic valve inflammation and calcification: opportunities for clinical translation
- 23 September 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (12) , 1809-1811
Open AccessoxLDL-induced aortic valve inflammation and calcification: opportunities for clinical translation
- Open Access
- 28 December 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 101, 103434
2D echocardiography video to 3D heart shape reconstruction for clinical application
- 28 December 2024
- Published by Elsevier in Medical Image Analysis
- Vol. 101, 103434
Open Access2D echocardiography video to 3D heart shape reconstruction for clinical application
- 25 December 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (2) , 286-294
Higher 1‐year mortality on rest days in patients with acute coronary syndromes and decompensated heart failure—A SPUM‐ACS sub‐study
Background: Acute coronary syndromes (ACS) occurring on rest days have been associated with higher mortality, but the current literature remains inconsistent in this regard. This study included ACS patients presenting with acute decompensated heart failure (ADHF) investigating the relationship between time of coronary catheterization and outcomes.Methods: Analyses were performed from the prospective, multicentric Special Program University Medicine Acute Coronary Syndromes and Inflammation (SPUM‐ACS) Cohort. Patients were divided into two groups according to time of coronary catheterization on either workdays (Monday, 00:00 to Friday, 23:59) or rest days (Saturday, 00:00 to Sunday, 23:59 and public holidays). ADHF was defined by Killip Class III or IV upon presentation. Patients were followed over 1 year.Results: Out of 4787 ACS patients enrolled in the SPUM‐ACS Cohort, 207 (4.3%) presented with ADHF. 52 (25.1%) and 155 (74.9%) patients underwent coronary angiography on rest days or workdays, respectively. Baseline characteristics were similar among these groups. ACS patients with ADHF showed increased 1‐year mortality on rest days (34.6% vs. 17.4%, p‐value = 0.009). After correction for baseline characteristics, including the GRACE 2.0 Score, rest day presentation remained a significant predictor for 1‐year mortality (adjusted hazard ratio = 2.42 [95% confidence interval: 1.14–5.17], p‐value = 0.022).Conclusions: One‐year all‐cause mortality was high in ACS patients with ADHF and doubled for patients admitted on rest days. The present data support the association of a rest day effect and long‐term patient survival and indicate a need for further investigations.
- 25 December 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (2) , 286-294
Higher 1‐year mortality on rest days in patients with acute coronary syndromes and decompensated heart failure—A SPUM‐ACS sub‐study
Background: Acute coronary syndromes (ACS) occurring on rest days have been associated with higher mortality, but the current literature remains inconsistent in this regard. This study included ACS patients presenting with acute decompensated heart failure (ADHF) investigating the relationship between time of coronary catheterization and outcomes.Methods: Analyses were performed from the prospective, multicentric Special Program University Medicine Acute Coronary Syndromes and Inflammation (SPUM‐ACS) Cohort. Patients were divided into two groups according to time of coronary catheterization on either workdays (Monday, 00:00 to Friday, 23:59) or rest days (Saturday, 00:00 to Sunday, 23:59 and public holidays). ADHF was defined by Killip Class III or IV upon presentation. Patients were followed over 1 year.Results: Out of 4787 ACS patients enrolled in the SPUM‐ACS Cohort, 207 (4.3%) presented with ADHF. 52 (25.1%) and 155 (74.9%) patients underwent coronary angiography on rest days or workdays, respectively. Baseline characteristics were similar among these groups. ACS patients with ADHF showed increased 1‐year mortality on rest days (34.6% vs. 17.4%, p‐value = 0.009). After correction for baseline characteristics, including the GRACE 2.0 Score, rest day presentation remained a significant predictor for 1‐year mortality (adjusted hazard ratio = 2.42 [95% confidence interval: 1.14–5.17], p‐value = 0.022).Conclusions: One‐year all‐cause mortality was high in ACS patients with ADHF and doubled for patients admitted on rest days. The present data support the association of a rest day effect and long‐term patient survival and indicate a need for further investigations.
- Open Access
- 21 September 2023
- Published by Springer Nature in Research Square
Fully automated 4D cardiac modelling from 2D echocardiography for clinical applications
Transthoracic Echocardiography (TTE) is a crucial tool for assessing cardiac morphology and function quickly and non-invasively without ionizing radiation. However, the examination is subject to intra- and inter-user variability and recordings are often limited to 2D imaging and assessments of end-diastolic and end-systolic volumes. Current 3D TTE is time-consuming and provides lower image quality than 2D TTE. We have developed a novel, fully automated machine learning-based framework to generate a 4D (3D plus time) personalized model of the left ventricular (LV) blood pool. This digital twin was generated from specific 2D echocardiographic views employing deep neural networks, pre-trained on a synthetic dataset, and fine-tuned in a self-supervised manner using a novel optimization method for cross-sectional imaging data. This 4D model enabled detailed three dimensional analyses of LV systolic and diastolic function with high temporal resolution. Validation was performed on a multi-center dataset encompassing TTE exams of 144 patients with normal TTEs (controls) and 314 patients with acute myocardial infarction (AMI). LV volume measurements in controls derived from the digital twin showed a high correlation with the values from the clinical TTE reports (Pearson correlation coefficient of 0.7). In AMI patients, these novel biomarkers showed a high predictive value for survival (area under the curve (AUC) of 0.82 for 1-year all-cause mortality) and and excellent diagnostic value for infarct localisation and quantification, bearing the potential to improve diagnostic accuracy and risk assessment. Thus, our digital twin allows for fully automated robust LV shape analyses over time including contractility, relaxation, and regional wall motion abnormalities aiming at replacing expensive 3D imaging modalities with cheaper and more versatile 2D cardiac ultrasound.
- 21 September 2023
- Published by Springer Nature in Research Square
Open AccessFully automated 4D cardiac modelling from 2D echocardiography for clinical applications
Transthoracic Echocardiography (TTE) is a crucial tool for assessing cardiac morphology and function quickly and non-invasively without ionizing radiation. However, the examination is subject to intra- and inter-user variability and recordings are often limited to 2D imaging and assessments of end-diastolic and end-systolic volumes. Current 3D TTE is time-consuming and provides lower image quality than 2D TTE. We have developed a novel, fully automated machine learning-based framework to generate a 4D (3D plus time) personalized model of the left ventricular (LV) blood pool. This digital twin was generated from specific 2D echocardiographic views employing deep neural networks, pre-trained on a synthetic dataset, and fine-tuned in a self-supervised manner using a novel optimization method for cross-sectional imaging data. This 4D model enabled detailed three dimensional analyses of LV systolic and diastolic function with high temporal resolution. Validation was performed on a multi-center dataset encompassing TTE exams of 144 patients with normal TTEs (controls) and 314 patients with acute myocardial infarction (AMI). LV volume measurements in controls derived from the digital twin showed a high correlation with the values from the clinical TTE reports (Pearson correlation coefficient of 0.7). In AMI patients, these novel biomarkers showed a high predictive value for survival (area under the curve (AUC) of 0.82 for 1-year all-cause mortality) and and excellent diagnostic value for infarct localisation and quantification, bearing the potential to improve diagnostic accuracy and risk assessment. Thus, our digital twin allows for fully automated robust LV shape analyses over time including contractility, relaxation, and regional wall motion abnormalities aiming at replacing expensive 3D imaging modalities with cheaper and more versatile 2D cardiac ultrasound.
- Top Cited PapersOpen Access
- 17 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (2) , 89-103
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare ‘The Good’ (repair and defence) while treating ‘The Bad’ (smouldering RIR) and capturing ‘The Ugly’ (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.
- 17 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (2) , 89-103
Top Cited PapersOpen AccessInflammation in acute myocardial infarction: the good, the bad and the ugly
Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare ‘The Good’ (repair and defence) while treating ‘The Bad’ (smouldering RIR) and capturing ‘The Ugly’ (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.